5,620 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by Bleakley Financial Group LLC

Bleakley Financial Group LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 5,620 shares of the life sciences company’s stock, valued at approximately $751,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Capital Investment Services of America Inc. increased its position in shares of Illumina by 2.0% in the 4th quarter. Capital Investment Services of America Inc. now owns 84,617 shares of the life sciences company’s stock valued at $11,307,000 after acquiring an additional 1,651 shares during the period. Stratos Wealth Partners LTD. grew its stake in Illumina by 2.5% during the 4th quarter. Stratos Wealth Partners LTD. now owns 6,534 shares of the life sciences company’s stock valued at $873,000 after purchasing an additional 160 shares during the last quarter. E. Ohman J or Asset Management AB increased its holdings in shares of Illumina by 7.7% in the fourth quarter. E. Ohman J or Asset Management AB now owns 6,965 shares of the life sciences company’s stock valued at $931,000 after purchasing an additional 500 shares during the period. Mather Group LLC. raised its stake in shares of Illumina by 432.5% in the fourth quarter. Mather Group LLC. now owns 820 shares of the life sciences company’s stock worth $110,000 after purchasing an additional 666 shares during the last quarter. Finally, Trust Point Inc. acquired a new stake in shares of Illumina during the fourth quarter worth about $235,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

NASDAQ:ILMN opened at $111.06 on Monday. The stock has a 50 day moving average price of $136.70 and a 200 day moving average price of $135.43. The stock has a market cap of $17.61 billion, a PE ratio of -14.46 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. Equities research analysts expect that Illumina, Inc. will post 4.42 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on ILMN. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a report on Thursday, October 17th. Guggenheim cut their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday. Royal Bank of Canada decreased their target price on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research report on Friday. Morgan Stanley cut their price target on Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Canaccord Genuity Group decreased their price objective on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a report on Friday. Nine investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $161.40.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.